Investigation on metabolism of cisplatin resistant ovarian cancer using a genome scale metabolic model and microarray data - PubMed (original) (raw)

Investigation on metabolism of cisplatin resistant ovarian cancer using a genome scale metabolic model and microarray data

Ehsan Motamedian et al. Iran J Basic Med Sci. 2015 Mar.

Abstract

Objectives: Many cancer cells show significant resistance to drugs that kill drug sensitive cancer cells and non-tumor cells and such resistance might be a consequence of the difference in metabolism. Therefore, studying the metabolism of drug resistant cancer cells and comparison with drug sensitive and normal cell lines is the objective of this research.

Material and methods: Metabolism of cisplatin resistant and sensitive A2780 epithelial ovarian cancer cells and normal ovarian epithelium has been studied using a generic human genome-scale metabolic model and transcription data.

Result: The results demonstrate that the most different metabolisms belong to resistant and normal models, and the different reactions are involved in various metabolic pathways. However, large portion of distinct reactions are related to extracellular transport for three cell lines. Capability of metabolic models to secrete lactate was investigated to find the origin of Warburg effect. Computational results introduced SLC25A10 gene, which encodes mitochondrial dicarboxylate transporter involved in exchanging of small metabolites across the mitochondrial membrane that may play key role in high growing capacity of sensitive and resistant cancer cells. The metabolic models were also used to find single and combinatorial targets that reduce the cancer cells growth. Effect of proposed target genes on growth and oxidative phosphorylation of normal cells were determined to estimate drug side-effects.

Conclusion: The deletion results showed that although the cisplatin did not cause resistant cancer cells death, but it shifts the cancer cells to a more vulnerable metabolism.

Keywords: Cisplatin resistance; Drug target; Lactate; Metabolism; Microarray; Warburg effect.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Number of reactions in each pathways which are present a) in resistant model and absent from sensitive model, b) in sensitive model and absent from resistant model, c) in resistant model and absent from normal model, d) in sensitive model and absent from normal model, e) in normal model and absent from resistant model, b) in normal model and absent from sensitive model

Figure 2

Figure 2

Growth rate sensitivity to lactate secretion rate for various cell lines

Figure 3

Figure 3

Change of maximum oxygen uptake rate in different lactate secretion rates for various cell lines at optimal growth

Figure 4

Figure 4

Change of maximum ATP synthase activity in different lactate secretion rates for various cell lines at optimal growth

References

    1. Li M, Balch C, Montgomery J, Jeong M, Chung J, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Medical Genomics. 2009;2:34. - PMC - PubMed
    1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage iii and stage iv ovarian cancer. N Engl J Med. 1996;334:1–6. - PubMed
    1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–516. - PubMed
    1. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63:12–31. - PubMed
    1. Bordbar A, Palsson BO. Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J Intern Med. 2012;271:131–141. - PMC - PubMed

LinkOut - more resources